BioSpaceOriginal article
Viking achieves 'maintenance trifecta' as GLP-/GIP dual agonist exceeds expectations
Data ReadoutpositiveVK2735Positive
AI Analysis
Summary
Viking Therapeutics' VK2735, a GLP-1/GIP dual agonist, demonstrated robust and maintained weight loss when patients transitioned to less frequent dosing, meeting expectations and driving a 30% stock increase.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
VK2735 met expectations with robust weight loss largely maintained at less frequent dosing
Importance:7/10
Sentiment:
0.85
GLP-1GIPdual agonistweight lossdata readoutstock positive
Related Companies
Read the original article
Published by BioSpace on September 22, 2026 4:02 PM